{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:11:38Z","timestamp":1779361898508,"version":"3.51.4"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["17008CR001\/VP1"],"award-info":[{"award-number":["17008CR001\/VP1"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["UG1 EY028088"],"award-info":[{"award-number":["UG1 EY028088"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"crossref","award":["UG1 EY028088"],"award-info":[{"award-number":["UG1 EY028088"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["UG1EY030833"],"award-info":[{"award-number":["UG1EY030833"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"crossref","award":["UG1EY030833"],"award-info":[{"award-number":["UG1EY030833"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R01EY025350"],"award-info":[{"award-number":["R01EY025350"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["L40-EY028421"],"award-info":[{"award-number":["L40-EY028421"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005595","name":"University of California","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005595","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>The World Health Organization (WHO) recommends continuing azithromycin mass drug administration (MDA) for trachoma until endemic regions drop below 5% prevalence of active trachoma in children aged 1\u20139 years. Azithromycin targets the ocular strains of <jats:italic>Chlamydia trachomatis<\/jats:italic> that cause trachoma. Regions with low prevalence of active trachoma may have little if any ocular chlamydia, and, thus, may not benefit from azithromycin treatment. Understanding what happens to active trachoma and ocular chlamydia prevalence after stopping azithromycin MDA may improve future treatment decisions. We systematically reviewed published evidence for community prevalence of both active trachoma and ocular chlamydia after cessation of azithromycin distribution. We searched electronic databases for all peer-reviewed studies published before May 2020 that included at least 2 post-MDA surveillance surveys of ocular chlamydia and\/or the active trachoma marker, trachomatous inflammation\u2013follicular (TF) prevalence. We assessed trends in the prevalence of both indicators over time after stopping azithromycin MDA. Of 140 identified studies, 21 met inclusion criteria and were used for qualitative synthesis. Post-MDA, we found a gradual increase in ocular chlamydia infection prevalence over time, while TF prevalence generally gradually declined. Ocular chlamydia infection may be a better measurement tool compared to TF for detecting trachoma recrudescence in communities after stopping azithromycin MDA. These findings may guide future trachoma treatment and surveillance efforts.<\/jats:p>","DOI":"10.1371\/journal.pntd.0009491","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T17:26:07Z","timestamp":1625765167000},"page":"e0009491","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Stopping azithromycin mass drug administration for trachoma: A systematic review"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7834-8213","authenticated-orcid":true,"given":"Hamidah","family":"Mahmud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6816-5560","authenticated-orcid":true,"given":"Emma","family":"Landskroner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdou","family":"Amza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solomon","family":"Aragie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William W.","family":"Godwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5387-783X","authenticated-orcid":true,"given":"Anna","family":"de Hostos Barth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1962-5321","authenticated-orcid":true,"given":"Kieran S.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8216-0240","authenticated-orcid":true,"given":"Thomas M.","family":"Lietman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0763-399X","authenticated-orcid":true,"given":"Catherine E.","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,7,8]]},"reference":[{"key":"pntd.0009491.ref001","unstructured":"WHO. [cited 2021 Feb 10]. Available from: https:\/\/www.who.int\/blindness\/causes\/trachoma\/en\/."},{"issue":"4","key":"pntd.0009491.ref002","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1128\/CMR.17.4.982-1011.2004","article-title":"Diagnosis and assessment of trachoma","volume":"17","author":"AW Solomon","year":"2004","journal-title":"Clin Microbiol Rev"},{"key":"pntd.0009491.ref003","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3389\/fcimb.2017.00438","article-title":"Characterization of the growth of Chlamydia trachomatis in in vitro-generated stratified epithelium","volume":"7","author":"AT Nogueira","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"issue":"4","key":"pntd.0009491.ref004","first-page":"477","article-title":"A simple system for the assessment of trachoma and its complications","volume":"65","author":"B Thylefors","year":"1987","journal-title":"Bull World Health Organ"},{"issue":"19","key":"pntd.0009491.ref005","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1056\/NEJMoa040979","article-title":"Mass treatment with single-dose azithromycin for trachoma","volume":"351","author":"AW Solomon","year":"2004","journal-title":"N Engl J Med"},{"issue":"10","key":"pntd.0009491.ref006","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1001\/jama.295.10.1142","article-title":"Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma","volume":"295","author":"JD Chidambaram","year":"2006","journal-title":"JAMA"},{"issue":"8","key":"pntd.0009491.ref007","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1371\/journal.pntd.0000507","article-title":"Importance of coverage and endemicity on the return of infectious trachoma after a single mass antibiotic distribution","volume":"3","author":"T Lakew","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"pntd.0009491.ref008","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/09286586.2019.1597129","article-title":"Community-level association between clinical trachoma and ocular chlamydia infection after MASS azithromycin distribution in a mesoendemic region of Niger","volume":"26","author":"A Amza","year":"2019","journal-title":"Ophthalmic Epidemiol"},{"issue":"12","key":"pntd.0009491.ref009","first-page":"1840","article-title":"Ocular chlamydia trachomatis infection under the surgery, antibiotics, facial cleanliness, and environmental improvement strategy in Amhara, Ethiopia, 2011\u20132015","volume":"67","author":"SD Nash","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pntd.0009491.ref010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09286586.2017.1293693","article-title":"Evaluation of a single dose of azithromycin for trachoma in low-prevalence communities","volume":"26","author":"N Wilson","year":"2019","journal-title":"Ophthalmic Epidemiol."},{"issue":"5","key":"pntd.0009491.ref011","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/8451","article-title":"Global elimination of trachoma: how frequently should we administer mass chemotherapy?","volume":"5","author":"T Lietman","year":"1999","journal-title":"Nat Med"},{"issue":"4","key":"pntd.0009491.ref012","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1086\/526777","article-title":"Complete elimination is a difficult goal for trachoma programs in severely affected communities","volume":"46","author":"DA Gill","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"9179","key":"pntd.0009491.ref013","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0140-6736(98)12387-5","article-title":"Azithromycin in control of trachoma","volume":"354","author":"J Schachter","year":"1999","journal-title":"Lancet"},{"issue":"Suppl 5","key":"pntd.0009491.ref014","doi-asserted-by":"crossref","first-page":"S519","DOI":"10.1093\/infdis\/jiz691","article-title":"Trachoma prevalence after discontinuation of mass azithromycin distribution","volume":"221","author":"W Godwin","year":"2020","journal-title":"J Infect Dis"},{"issue":"8","key":"pntd.0009491.ref015","doi-asserted-by":"crossref","first-page":"e1002633","DOI":"10.1371\/journal.pmed.1002633","article-title":"Mass azithromycin distribution for hyperendemic trachoma following a cluster-randomized trial: A continuation study of randomly reassigned subclusters (TANA II)","volume":"15","author":"JD Keenan","year":"2018","journal-title":"PLoS Med"},{"issue":"1","key":"pntd.0009491.ref016","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S1473-3099(18)30444-4","article-title":"Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review","volume":"19","author":"KS O\u2019Brien","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"pntd.0009491.ref017","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12886-020-01776-4","article-title":"Azithromycin Reduction to Reach Elimination of Trachoma (ARRET): study protocol for a cluster randomized trial of stopping mass azithromycin distribution for trachoma.","volume":"21","author":"A Amza","year":"2021","journal-title":"BMC Ophthalmol."},{"issue":"3","key":"pntd.0009491.ref018","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/trstmh\/traa170","article-title":"Implications of the COVID-19 pandemic in eliminating trachoma as a public health problem","volume":"115","author":"S Blumberg","year":"2021","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"2","key":"pntd.0009491.ref019","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"PA Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"103208","key":"pntd.0009491.ref020","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: Building an international community of software platform partners.","volume":"95","author":"PA Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"pntd.0009491.ref021","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"JPT Higgins","year":"2011","journal-title":"BMJ"},{"key":"pntd.0009491.ref022","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"JA Sterne","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"pntd.0009491.ref023","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1167\/iovs.05-0326","article-title":"Spatial clustering of ocular chlamydial infection over time following treatment, among households in a village in Tanzania","volume":"47","author":"AT Broman","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"pntd.0009491.ref024","doi-asserted-by":"crossref","first-page":"e835","DOI":"10.1371\/journal.pntd.0000835","article-title":"Profound and sustained reduction in Chlamydia trachomatis in The Gambia: a five-year longitudinal study of trachoma endemic communities","volume":"4","author":"MJ Burton","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"issue":"9467","key":"pntd.0009491.ref025","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(05)61029-X","article-title":"Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study","volume":"365","author":"MJ Burton","year":"2005","journal-title":"Lancet"},{"issue":"7","key":"pntd.0009491.ref026","first-page":"632","article-title":"Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma","volume":"79","author":"N Fraser-Hurt","year":"2001","journal-title":"Bull World Health Organ"},{"issue":"6","key":"pntd.0009491.ref027","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1086\/342298","article-title":"Disappearance of trachoma from Western Nepal","volume":"35","author":"H Jha","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pntd.0009491.ref028","doi-asserted-by":"crossref","first-page":"482","DOI":"10.4269\/ajtmh.2010.09-0315","article-title":"Clinical activity and polymerase chain reaction evidence of chlamydial infection after repeated mass antibiotic treatments for trachoma","volume":"82","author":"JD Keenan","year":"2010","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"pntd.0009491.ref029","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1371\/journal.pntd.0000376","article-title":"Reduction and return of infectious trachoma in severely affected communities in Ethiopia","volume":"3","author":"T Lakew","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"pntd.0009491.ref030","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10792-010-9360-5","article-title":"Trachoma control in two Central Australian Aboriginal communities: a case study","volume":"30","author":"VC Lansingh","year":"2010","journal-title":"Int Ophthalmol"},{"issue":"6","key":"pntd.0009491.ref031","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jama.292.6.721","article-title":"Feasibility of eliminating ocular Chlamydia trachomatis with repeat mass antibiotic treatments","volume":"292","author":"M Melese","year":"2004","journal-title":"JAMA"},{"issue":"7","key":"pntd.0009491.ref032","doi-asserted-by":"crossref","first-page":"e0007559","DOI":"10.1371\/journal.pntd.0007559","article-title":"Ocular immune responses, Chlamydia trachomatis infection and clinical signs of trachoma before and after azithromycin mass drug administration in a treatment na\u00efve trachoma-endemic Tanzanian community","volume":"13","author":"AM Ramadhani","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0009491.ref033","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.actatropica.2006.12.003","article-title":"Longitudinal evaluation of three azithromycin distribution strategies for treatment of trachoma in a sub-Saharan African country, Mali","volume":"101","author":"J-F Sch\u00e9mann","year":"2007","journal-title":"Acta Trop"},{"issue":"17","key":"pntd.0009491.ref034","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMc0706263","article-title":"Two doses of azithromycin to eliminate trachoma in a Tanzanian community","volume":"358","author":"AW Solomon","year":"2008","journal-title":"N Engl J Med"},{"issue":"6","key":"pntd.0009491.ref035","doi-asserted-by":"crossref","first-page":"e0178595","DOI":"10.1371\/journal.pone.0178595","article-title":"Treating village newcomers and travelers for trachoma: Results from ASANTE cluster randomized trial","volume":"12","author":"SK West","year":"2017","journal-title":"PLoS ONE"},{"issue":"9493","key":"pntd.0009491.ref036","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0140-6736(05)67529-0","article-title":"Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study","volume":"366","author":"SK West","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"pntd.0009491.ref037","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1167\/iovs.06-0625","article-title":"Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village","volume":"48","author":"SK West","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"pntd.0009491.ref038","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/archophthalmol.2011.46","article-title":"Slow resolution of clinically active trachoma following successful mass antibiotic treatments","volume":"129","author":"JD Keenan","year":"2011","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"pntd.0009491.ref039","doi-asserted-by":"crossref","first-page":"e0005080","DOI":"10.1371\/journal.pntd.0005080","article-title":"The relationship between active trachoma and ocular Chlamydia trachomatis infection before and after mass antibiotic treatment","volume":"10","author":"AM Ramadhani","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"pntd.0009491.ref040","doi-asserted-by":"crossref","first-page":"e0003682","DOI":"10.1371\/journal.pntd.0003682","article-title":"The distribution of ocular Chlamydia prevalence across Tanzanian communities where trachoma is declining","volume":"9","author":"SA Rahman","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"pntd.0009491.ref041","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/trstmh\/traa171","article-title":"Modelling trachoma post-2020: opportunities for mitigating the impact of COVID-19 and accelerating progress towards elimination","volume":"115","author":"A Borlase","year":"2021","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"2","key":"pntd.0009491.ref042","doi-asserted-by":"crossref","first-page":"e0004462","DOI":"10.1371\/journal.pntd.0004462","article-title":"Control of trachoma from Achham District, Nepal: A cross-sectional study from the Nepal national trachoma program","volume":"10","author":"BP Pant","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"9","key":"pntd.0009491.ref043","doi-asserted-by":"crossref","first-page":"e0004906","DOI":"10.1371\/journal.pntd.0004906","article-title":"Cross-sectional surveys of the prevalence of follicular trachoma and trichiasis in The Gambia: Has elimination been reached?","volume":"10","author":"SE Burr","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"pntd.0009491.ref044","doi-asserted-by":"crossref","first-page":"e0009343","DOI":"10.1371\/journal.pntd.0009343","article-title":"Serology, infection, and clinical trachoma as tools in prevalence surveys for re-emergence of trachoma in a formerly hyperendemic district","volume":"15","author":"M Odonkor","year":"2021","journal-title":"PLoS Negl Trop Dis"}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009491","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T17:26:57Z","timestamp":1625765217000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009491"}},"subtitle":[],"editor":[{"given":"Jeremiah M.","family":"Ngondi","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":44,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0009491","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,8]]}}}